[go: up one dir, main page]

US3654257A - Diazo derivatives of imidazole carboxylic acid esters - Google Patents

Diazo derivatives of imidazole carboxylic acid esters Download PDF

Info

Publication number
US3654257A
US3654257A US51747*A US3654257DA US3654257A US 3654257 A US3654257 A US 3654257A US 3654257D A US3654257D A US 3654257DA US 3654257 A US3654257 A US 3654257A
Authority
US
United States
Prior art keywords
carboxylate
imidazole
methyl
percent
triazeno
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US51747*A
Inventor
Charles A Krauth
Yoder Fulmer Shealy
Clinton Allen O'dell
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CHARLES A KRAUTH
CLINTON ALLEN O DELL
Original Assignee
CHARLES A KRAUTH
CLINTON ALLEN O DELL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CHARLES A KRAUTH, CLINTON ALLEN O DELL filed Critical CHARLES A KRAUTH
Application granted granted Critical
Publication of US3654257A publication Critical patent/US3654257A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/48—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with two nitrogen atoms as the only ring hetero atoms
    • A01N43/50—1,3-Diazoles; Hydrogenated 1,3-diazoles

Definitions

  • the present invention relates to certain derivatives of the imidazole heterocyclic ring which is a S-membered diazo structure containing two nitrogen atoms and two double bonds. Since tautomeric structures are possible, substituents in the 4 and positions are written thus, 4(or 5) and 5 (or 4).
  • the present compounds are diazo derivatives of imidazole carboxylic acid esters. The formulas for the compounds of the present invention and subsequently triazeno products are set out below:
  • R C -C alkyl, diethylaminoethyl, and acid addition salts thereof,
  • R alkyl, substituted alkyl, aryl,
  • R H, alkyl, substituted alkyl and aryl.
  • the preferred compounds are compounds in which at least one of the R R and R substituents is lower alkyl.
  • a most preferred compound is methyl 5(or 4)-(3,3-dimethyl-l-triazeno)imidazole-4(or 5 )-carboxylate which is the compound taught in Example 1 and teaches a compound in which the 3 R substituents are symmerically methyl.
  • Operable diazo compounds include those where lower alkyl is defined to have 1-8 carbon atoms.
  • Certain compounds of the present invention have exhibited extremely broad antimicrobial activity in that in addition to any broad antibacterial activity against gram negative, gram positive and other groups, they also exhibit strong antifungal activity. Certain other compounds of the present invention additionally antialgal and antiprotozoal activity.
  • the present group of compounds having combined antifungal and antibacterial activity find present utility in sanitizing sheets, bed linen, etc. in hospitals. Aqueous solutions and solvent dispersions in concentrations of only a few parts per million have exerted powerful sanitizing action.
  • the compounds of the present invention may be conveniently prepared using as known starting materials the R 5(or 4)-a-minoimidazole-4(0r 5)-carboxylate where R, is selected to provide the proper ester substituent.
  • Conventional nitrite diazotization of the compounds in the cold with excess mineral acid gives the intermediate diazo compounds which may be extracted with organic solvents and separated as desired. Excess nitrite is destroyed by known reagents such as sulfamic acid.
  • the triazeno moiety providing the R and R of the final compounds may be achieved by amination of the diazo intermediate compound at an alkaline pH of 9-10 using a primary or secondary amine with the desired substituent groups.
  • the ester acid addition salts are prepared by reaction with the appropriate acid such as HCl to give more soluble compounds.
  • the triazeno compounds of the present invention may be recovered by extraction with a variety of organic solvents, followed by distillation. The more hydrophobic compounds precipitate more readily from hydrophilic type solvents.
  • a particularly useful solvent for purifying the triazeno compound is a mixture of ethylacetate-hexane.
  • the compounds of the present invention in addition to fair aqueous solubility, are generally soluble in polar and organic solvents such as lower aliphatic alcohols, such as methanol and ethanol; halogenated compounds of the methane series such as chloroform; alkyl esters of aliphatic acids such as ethyl acetate.
  • polar and organic solvents such as lower aliphatic alcohols, such as methanol and ethanol; halogenated compounds of the methane series such as chloroform; alkyl esters of aliphatic acids such as ethyl acetate.
  • the ester acid addition salts such as hydrochloride, hydrobromide, hydroiodide find greater hydrophilic solubility due to aqueous affinity of the acid and this is particularly true of the mineral acid addition salt group.
  • Suitable salts are, for example, the ester acid addition salts from mineral acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid and orthophosphoric acid, or organic acids such as acetic acid, propionic acid, pivalic acid, succinic acid, maleic acid, fumaric acid, lactic acid, malic acid, tartaric acid, citric acid, gluconic acid, L-ascrobic acid, benzoic acid, salicylic acid, methyl sulfonic acid, ethyl disulfonic acid, p-toluenesulfonic acid, naphthalene disulfonic acid and ,B-hydroxyethyl sulfonic acid.
  • mineral acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid and orthophosphoric acid
  • organic acids such as acetic acid, propionic acid, pivalic acid, succinic acid, maleic acid, fumaric acid, lactic acid,
  • the instant compounds have present utility as sanitizing compounds.
  • a hospital blanket or a toy from the OT. department of the hospital when soiled and contaminated by a mixture of pathogenic organisms including both bacteria and fungi may be sanitized immediately by soaking or spraying the article with solutions of 50 to 250 ppm. of the active compound.
  • Aqueous solutions of the water-soluble acid addition salts of the esters, alcoholic sprays of the more hydrophobic compounds and foamite applications to other articles about the hospital, such as soiled rugs, illustrate the present utility of the compounds of this invention.
  • penicillin G is limited to acute bacteriostat action against gram positive bacteria.
  • Streptomycins widely used during the 1950s and active against both gram positive and gram negative bacteria have recently fallen in disfavor due to sensitivity of the auditory nerve to these drugs.
  • tetracyclines are the tetracyclines. These drugs, still in the phase of development and modification, are active against a wide range of gram positive and gram negative bacteria as well as the rickettsia which causes Rocky Mountain spotted fever, typhus, etc.
  • chloramphenicol is a bacteriostat with a range roughly paralleling the tetracyclines and a greater potency against many organisms.
  • the drug can cause serious and sometimes fatal blood dyscrasias and its use is limited.
  • none has a utility as an antifungal agent.
  • amphotericin B is without elfect on bacteria, rickettsia and viruses (Goodman and Gilman, The Pharmacological Basis of Therapeutics, third ed. (1965), page 1294).
  • nystatin a popular polyene fungistat is also stated to be without results or without effect on bacteria, protozoa or viruses. Finally, the equally popular antifungal griseofulvin is devoid of any bacterial activity.
  • the compounds of the present invention have prospec tive utility to fill this clinical need in that they combine broad antibacterial activity with antifungal activity.
  • the triazeno imidazole carboxylic acid esters and the S-diazoimidazole-4-carboxylic acid esters of this invention have inhibitory activity in several different types of microorganisms.
  • Methyl (or 4)-(3,3-dimethyl 1 triazeno)-imidazole-4(or 5)-carb0xylate, the compound of Example 1 for example, inhibits the growth of a wide variety of yeast, filamentous fungi, gram positive and gram negative bacteria, mycobacteria and algae.
  • the antimicrobial activity of these compounds is exemplified by inhibition by methyl 5(or 4)-(3,3 dimethyl-l-triazeno)imidazole-4(or 5)-carboxylate (Example 1), ethyl 5(or 4)-(3- cyclohexyl-3-methyl-l-triazeno)imidazole 4(or 5)-carboxylate (Example 9), or methyl 5-diazoimidazole-4-carboxylate (Example 4) of Streptococcus faecalis, Staphylococcus aureus Bactillus substil is, Sarcina lutes, Escherichia 4 monas aeruginos'a, Mycobacterium smegmatz's, Candida albicans, Hansenula wingal, Saccharomyces cerevisiae, Fusarium oxysporum, Penicillium roquefortz', Chlorelia pyreno
  • the few medicinal antifungal agents today are essentially devoid of antibacterial activity and conversely the antibacterial drugs are ineffective against pathogenic fungi.
  • Enhanced importance and novelty therefore derive from inhibitory activity against both the fungi and the bacteria, including mycobacteria, by a single type of structure such as the present compounds, for example, the methyl 5( or 4)-(3,3-dimethyl-l-triazeno) imidaZole-4(or 5)-carboxylate.
  • the economic importance of plant type of germs, both fungal and bacterial make apparent the importance of novel antifungal and antibacterial compounds to agriculture and horticulture.
  • the triazeno esters may be prepared conveniently from the ester of the corresponding amino compound of the 4(or 5)-carboxylic acid and treating this amino compound with a diazotising reagent and an acid.
  • the starting materials are well known in the art, for example, the methyl 4(or 5)-amino imidazole-5(or 4)-carboxylate used in Examples 1, 2, 3, 4 or 7 and 19 is cited in the Jour. Gen. Chem., USSR, 29, 2366-2368 (1959), a translation of Russian Zhur. Obshchei Khim., 28, 2401 (1959).
  • This Russian article has not only prepared the methyl and ethyl esters, but the alkyl series including the mineral acid addition salts.
  • the process may be interrupted to recover the active but sporadically unstable diazo compounds in the form of the intermediate 5-diazoimidazole-4-carboxylic acid ester which may be conveniently extracted from the aqueous diazotisation mixture with organic solvents such as chloroform, or depending on water solubility may be recovered as a precipitate from the solution and collected by filtration.
  • organic solvents such as chloroform, or depending on water solubility
  • the diazo derivative may then be treated with an appropriate amine in a two-step or interrupted process to produce the final preferred triazeno compounds.
  • the production of the diazo compound or diazonium salt which is a nitrous acid derivative of the heterocyclic amine follows conventional procedure in the type reaction for the production of diazo compounds, as for example, set out in Karrer Organic Chemistry, 4th 'Ed., 1950, page 472.
  • the amine and the nitrite salt are reacted in approximately equimolar quantities in the presence of a general excess of at least 2.5 mols of mineral acid, as for example, hydrochloric acid used in many of the examples.
  • the reaction is carried out by immersing in an ice salt bath to reduce the temperature to a range of about -5.
  • the excess of the mineral acid serves to drive the reaction toward the right and the cold treatment is used because many diazo and diazonium compounds are unstable at high temperatures.
  • the diazo compound may be separately recovered.
  • the production of the triazeno compound is readily made after destruction of excess nitrite with an agent such as sulfamic acid and when the required primary or secondary amine is added the reaction goes at a slightly alkaline pH of 9-10.
  • the compound may be extracted with chloroform, recrystallized from methanol, dried and recovered as the triazeno compound.
  • the methyl 5(or 4)-(3,3-dimethyl-l-triazeno)imidazole-4(0r 5) carboxylate obtained in this manner displayed ultraviolet absorption maxima in methanol at 233 m and 328 m and prominent infrared absorption bands near 1695 cmfl, 1440 cmr 1315 cm.- 1070 cmr Analysis.-Calcd. for C7H11N5O2 (percent): C, 42.64; H, 5.63; N, 35.51. Found (percent): C, 42.90; H, 5.65; N, 35.44.
  • Example 2 Methyl 5 (or 4)-3-n-butyl-3-methyl-l-triazeno)imidazole- 4(or 5)-carboxylate
  • the procedure of Example 1 was employed with the following exceptions: (1) the reaction solution obtained after the addition of the water solution of sodium nitrite to the hydrochloric acid solution of methyl 5 (or 4)- aminoimidazole-4(or 5)- carboxylate was stirred for 0.5 hour, and (2) methyl-n-butylamine was used in lieu of 25% aqueous dimethylamine and was added in sufiicient quantity to raise the pH at least to 9. The product precipitated from the reaction mixture and was collected by filtration, washed well with water, and dried thoroughly at room temperature.
  • EXAMPLE 4 Methyl 5-diazoimidazole-4-carboxylate A solution of 10 g. of methyl 5(or 4)-aminoimidazole- 4(or 5 )-carboxylate in 200 ml. of 1 N hydrochloric acid was treated with activated carbon to remove colored impurities. To the filtrate immersed in an ice-salt bath was added dropwise during 5 min. a solution of 5.46 g. of sodium nitrite in 20 m1. of water. The reaction mixture was stirred for 1.5 hr. and then extracted 10 times with 200-ml. portions of chloroform. The extracts were combined, the total extract was washed with saturated sodium chloride solution, filtered, and dried with magnesium sulfate.
  • the filtrate from the drying agent was evaporated under reduced pressure at temperatures below 30, and the yellow crystalline methyl 5-diazonimidazole-4-carboxylate so obtained was dried further in a vacuum at room temperature; weight, 8.13 g. (75% yield); M.P. 96.
  • the ultraviolet absorption spectrum of methyl 5- diazoimidazole-4-carboxylate in phosphate buffer at pH 7 displayed a maximum at 314 m and a shoulder at 270 me; its infrared spectrum included prominent bands near 2180 cm.* due to the diazo group and near 1700 cm. due to the ester group.
  • EXAMPLE 5 Ethyl S-diazoimidazole-4-carboxylate To a solution of 1.36 g. of ethyl 5 (or 4)-aminoimidazole-4(or 5 )-carboxylate hydrochloride in 20 ml. of 1 N hydrochloric acid at 0 was added a solution of 546 mg. of sodium nitrite in 5 ml. of water. The pale yellow solution was stirred at 0 for 1 hour and then extracted with four 25-ml. portions of chloroform. The chloroform extracts Were combined, washed with a saturated solution of sodium chloride, dried with magnesium sulfate, filtered, and concentrated under reduced pressure at room temperature. The residual light yellow oil (1.1 g.) crystallized to a yellow crystalline solid; M.P. 45-46 dec. A strong band near 2200 cmrl, characteristic of the diazo group, was present in the infrared spectrum.
  • Part B.-A solution consisting of 12.5 ml. of N-methylethanolamine in 125 ml. of ethyl acetate was prepared and was shielded from light.
  • 3.14 g. of methyl 5-diazoimidazole-4-carboxylate was added in portions. This addition was made over a period of 1-1.5 hr., and the reaction mixture was stirred for an additional 2.5 hr. in the dark.
  • the precipitated product was collected by filtration, washed thoroughly with ethyl acetate, and dried under reduced pressure; weight, 4.4 g. (98% yield); M.P. 156-157 dec.
  • Part B To a solution of 5.0 g. of ethyl 5(or 4)- aminoimidazole-4(or 5)-carboxylate hydrochloride in 74 m1. of 1 N hydrochloric acid at 0 C. was added during a period of 15 min. a solution of 2.0 g. of sodium nitrite in 20 ml. of water. The resulting solution was stirred in an ice bath for 30 min., the excess nitrite was destroyed with sulfamic acid, and 30 ml. of methyl-n-butylamine Was then introduced. The mixture was stirred for 1.5 hr.
  • EXAMPLE 9 Ethyl 5(or 4)-(3-cyclohexyl-3-methyl-l-triazeno) imidazole-4 (or 5 -carboxylate Part A.--The procedure of Part A of Example 8 was applied to a reaction of ethyl 5-diazoirnidazole-4-carboxylate (4.5 g.) and methylcyclohexylarnine (20 ml.), instead of methyl-n-butylamine, in ethyl acetate (125 ml.), The reaction mixture was stirred for a period of 2 hr. at room temperature instead of the overnight-stirring of Example 8, Part A.
  • the white crystalline product obtained by filtering the reaction mixture represented a yield of 58% (4.31 g.); M.P. dec.
  • the infrared spectrum of this material was identical with that of the analytical sample of Part B.
  • a second crop of the same product amounting to a yield of 16.5% (1.25 g.) was obtained by diluting the filtrate from the first crop with hexane and chilling.
  • Part B The procedure of Part B of Example 8 was employed with the exception that methylcyclohexylarnine was used in lieu of methyl-n-butylamine.
  • the reaction mixture was filtered to remove a precipitate that represented a yield of 80% of ethyl 5(or 4)-(3-cyclohexyl- S-methyl-l-triazeno)imidazole-4(or 5)-carboxylate; M.P. l'68l70 with decomposition.
  • EXAMPLE 10 Ethyl 5(or 4)-(3,3-dimethyl-1-triazeno) imidazole-4( or 5)-carboxylate Part A.-Dimethylamine gas was passed into 75 ml. of ethyl acetate until 13.9 g. had been absorbed. To this solution, cooled with an ice bath, was added, within a 3-minute interval, a solution of 4.7 g. of ethyl 3-diazoimidazole-4 carboxylate in 25 ml. of ethyl acetate. A white solid began to precipitate almost immediately.
  • Part B The procedure of Part B of Example 8 was employed with the exception that 25% aqueous dimethylamine (110 ml.) was used in lieu of methyl-n-butylamine. After 1 hr. of stirring, the reaction mixture was extracted four times with chloroform. The extracts were combined; the total extract was washed with saturated aqueous sodium chloride solution and dried with magnesiurn sulfate; and the chloroform was evaporated under reduced pressure. From 10 g. of ethyl (or 4)-aminoimidazole-4(or 5 -carboxylate hydrochloride was obtained 9.54 g. of the dimethyltriazene derivative; M.P. 174- 175 dec.
  • the column was eluted successively with hexane, a mixture of hexane (60%) and acetone (40%). Evaporating the solvents under reduced pressure from the hexane-acetone eflluent, triturating the residual oil with hexane, and chilling the mixture resulted in the formation of light pink crystals that were separated by filtration, washed with hexane, and dried under reduced presusre, weight, 2.1 g.; M.P. 6465 dec. The acetone effluent from the Florisil column was treated in the same manner as the hexane-acetone efliuent and yielded an additional 967 mg.
  • Ultraviolet absorption maxima at 222 my and 326 mg and at 249 my. and 340 m were present in the spectra of this compound dissolved in 0.1 N hydrochloric acid and in 0.1 N aqueous sodium hydroxide, respectively.
  • the crude product was purified by treating an ethanol solution or an ethyl acetate solution of the crude material with activated carbon and then diluting the filtrates with water or with hexane, respectively.
  • the catalyst was removed by filtration under a current of nitrogen, the filtrate was saturated with dry hydrogen chloride, and the mixture was concentrated under reduced pressure until a white solid (6.1 g.) remained.
  • the White solid was dissolved in a mixture of ml. of ether and 15 ml. of ethanol, the turbid mixture was filtered, and the colorless filtrate was diluted, while hot, with 100 ml. of hexane.
  • EXAMPLE Ethyl 5 (or 4) -[3-(2-hydroxyethyl) -3-methyl-1-triazeno]- imidazole-4 (or 5) -carboxylate The procedure of Part A of Example 8 was employed except that N-methylethanolamine was used in lieu of methyl-n-butylamine. The reaction mixture was diluted with cyclohexane, and, after 0.5 hr. of stirring, the product was collected by filtration, washed with cyclohexane, and dried under reduced pressure at 56; yield, M.P., 138-l39 dec. This compound may be further purified by recrystallization from a mixture of ethanol and cyclohexane, M.P. 140 dec.
  • EXAMPLE 21 Ethyl 5 (or 4) 3-methyl-3 -n-octyl-l-triazeno imidazole- 4(or 5 -carboxylate
  • the method of part B of Example 7 was employed except that methyl-n-octylamine was used in lieu of N- methylethanolamine and ethyl 5-diazoimidazole-4-carboxylate was employed in lieu of methyl S-diazoimidazole- 4-carboxylate.
  • the reaction mixture after 2 hr. of stirring, was diluted with cyclohexane.
  • EXAMPLE 22 Ethyl 5 (or 4)-(3,3-dicyclohexyl-l-triazeno)imidazole- 4(or 5)-carboxylate
  • the procedure of Example 21 was employed with the exception that dicyclohexylamine was used in lieu of methyl-n-octylamine. From 400 mg. of the diazo compound there was obtained 550 mg. (65% yield) of the desired product; M.P. 170-175 dec. An ethanol solution of the white solid was treated with activated carbon, the filtrate was diluted with cyclohexane, and the resulting solution was concentrated under reduced pressure to a white solid that was washed with hexane and dried under reduced pressure at 56; M.P. 170-175 dec.
  • EXAMPLE 23 2-diethylaminoethyl 5 (or 4) 3 ,3-dimethyl-1-triazeno imidazole-4 (or 5 -carboxylate
  • the method employed was similar to that of Example 1 with some modifications in the details of the operations.
  • a solution of mg. of sodium nitrite in 5 ml. of water was added at 0 to a solution of 449 mg. of 2-diethylaminoethyl 5(or 4)-aminoimidazole-4(or 5)-carboxylate hydrochloride in 25 ml. of 1 N hydrochloric acid, and the resulting solution was stirred at 0 C. for 45 min.
  • EXAMPLE 24 Z-diethylaminoet-hyl (or 4) 3 -cyclohexyl-3 -methyll-triazeno) imidazole-4 (or 5 -carboxylate
  • the method of Example 23 was employed except that methylcycolhexylamine, in excess, was used in lieu of 25% aqueous dimethylamine, the reaction time was 2 hr. instead of 1 hr., and only chloroform (3 portions) was used to extract the product.
  • the syrup obtained from the chloroform was applied to a column of Florisil. The column was eluted successively with hexane and with a 1:1 mixture of hexane and acetone.
  • EXAMPLE 25 Z-diethylaminoethyl 5 (or 4)-aminoimidazole-4 (or 5 carboxylate hydrochloride
  • COMPARATIVE EXAMPLE 26' Compound I, 5 (or 4) (3,3 dimethyl 1 triazeno) imidazole-4( or 5)-carboxamide, has the same structure as Example 1 except that the ester group of Example 1 has been replaced by an amide group in Compound I.
  • Example 1 inhibited all of these fungi.
  • Example 1 (2) Among the dysenteny bacteria, Compound I did not inhibit the growth of three species (S. flexneri, S. dysenteriae, and S. bovlii) of Shigella at 100 micrograms per disc, Example 1 did.
  • Example 1 inhibited Proteus mirabilis and 7 strains of Proteas vulgaris, several strains of Pseudomonas aeruginosa, and more than 25 strains of Staphylococcus aureus. At the same concentration Compound I did not inhibit these bacteria except for a trace of inhibition of 2 strains of S.
  • Example 1 At a concentration of l mcg./ disc, Example 1 produced inhibitory zones of 20 millimeters, or greater, in diameter in tests versus four species of the genus Mycobacterium; at the same concentration, Compound I produced only trace inhibition.
  • Compound I is not inhibitory to fungi, whereas Example 1 inhibits a broad spectrum of fungi. Furthermore, Compound I is inferior to Example 1 in antibacterial activity.
  • R is C -C alkyl, diethylaminoethyl, or mineral acid addition salts thereof.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Dentistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Pest Control & Pesticides (AREA)
  • Agronomy & Crop Science (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

THE PRESENT INVENTION RELATES TO CERTAIN DERIVATIVES OF THE IMIDAZOLE HETEROCYCLIC RING WHICH IS A 5-MEMBERED DIAZO STRUCTURE CONTAINING TWO NITROGEN ATOMS AND TWO DOUBLE BONDS. SINCE TAUTOMERIC STRUCTURES ARE POSSIBLE, SUBSTITUENTS IS THE 4 AND 5 POSITIONS ARE WRITTEN THUS, 4 (OR 5) AND 5(OR 4). THE PERCENT COMPOUNDS ARE DIAZO DERIVATIVES OF IMIDAZOLE CARBOXYLIC ACID ESTERS. THE FORMULAS FOR THE COMPOUNDS OF THE PRESENT INVENTION AND SUBSEQUENTLY TRIAZENO PRODUCTS ARE SET OUT BELOW:

FORMULA I

4(OR 5)-(R1-COO-),5(OR 4)-((+)N2-)IMIDAZOLE,

4-(R1-COO-),5-(R2-N(-R3)-N=N-)IMIDAZOLE

R1=C1-C8 ALKYL, DIETHYLAMINOETHYL, AND ACID ADDITION SALTS THEROF, R2=ALKYL, SUBSTITUTED ALKYL, ARYL, R3=H, ALKYL, SUBSTITUTED ALKYL AND ARYL.

Description

Patented Apr. 4, 1972 3,654,257 DIAZO DERIVATIVES F IMIDAZOLE CARBOXYLIC ACID ESTERS Charles A. Krauth, Taejon Presbyterian College, Teajon, Korea, and Yoder Fulmer Shealy and Clinton Allen 0l2)0ell, both of 2000 9th Ave. 8., Birmingham, Ala. 35 4 No Drawing. Original application Sept. 14, 1967, Ser. No. 667,659. Divided and this application Apr. 28, 1970, Ser. No. 51,747
Int. Cl. A61l13/00;C07c 113/00, 115/00 US. Cl. 260--141 4 Claims ABSTRACT OF THE DISCLOSURE The present invention relates to certain derivatives of the imidazole heterocyclic ring which is a S-membered diazo structure containing two nitrogen atoms and two double bonds. Since tautomeric structures are possible, substituents in the 4 and positions are written thus, 4(or 5) and 5 (or 4). The present compounds are diazo derivatives of imidazole carboxylic acid esters. The formulas for the compounds of the present invention and subsequently triazeno products are set out below:
R =C -C alkyl, diethylaminoethyl, and acid addition salts thereof,
R =alkyl, substituted alkyl, aryl,
R =H, alkyl, substituted alkyl and aryl.
This application is a division of application Ser. No. 667,659 filed Sept. 14, 1967.
The preferred compounds are compounds in which at least one of the R R and R substituents is lower alkyl. A most preferred compound is methyl 5(or 4)-(3,3-dimethyl-l-triazeno)imidazole-4(or 5 )-carboxylate which is the compound taught in Example 1 and teaches a compound in which the 3 R substituents are symmerically methyl. Operable diazo compounds include those where lower alkyl is defined to have 1-8 carbon atoms.
Certain compounds of the present invention have exhibited extremely broad antimicrobial activity in that in addition to any broad antibacterial activity against gram negative, gram positive and other groups, they also exhibit strong antifungal activity. Certain other compounds of the present invention additionally antialgal and antiprotozoal activity. The present group of compounds having combined antifungal and antibacterial activity find present utility in sanitizing sheets, bed linen, etc. in hospitals. Aqueous solutions and solvent dispersions in concentrations of only a few parts per million have exerted powerful sanitizing action.
The compounds of the present invention may be conveniently prepared using as known starting materials the R 5(or 4)-a-minoimidazole-4(0r 5)-carboxylate where R, is selected to provide the proper ester substituent. Conventional nitrite diazotization of the compounds in the cold with excess mineral acid gives the intermediate diazo compounds which may be extracted with organic solvents and separated as desired. Excess nitrite is destroyed by known reagents such as sulfamic acid.
The triazeno moiety providing the R and R of the final compounds may be achieved by amination of the diazo intermediate compound at an alkaline pH of 9-10 using a primary or secondary amine with the desired substituent groups.
The shift of the pH from the acid of the diazo preparation wherein the reaction mixture was strongly acid to the triazeno preparation where the reaction mixture is slightly basic is usually achieved by the simple addition of the basic amine without subsidiary alkaline reagents.
The ester acid addition salts are prepared by reaction with the appropriate acid such as HCl to give more soluble compounds. The triazeno compounds of the present invention may be recovered by extraction with a variety of organic solvents, followed by distillation. The more hydrophobic compounds precipitate more readily from hydrophilic type solvents. A particularly useful solvent for purifying the triazeno compound is a mixture of ethylacetate-hexane.
PRIOR ART The prior art picture in which the present invention falls is limited in scope. A portion of the present development was described in the following article, A New Antifungal and Antibacterial .Agent, Methyl 5 (or 4)-(3,3- dimethyl-l triazeno)irnidazole 4(or 5) carboxylate," Shealy, et al. Jour. of American Pharmaceutical Association, volume 56, No. 1, (January 1967), pages 147-148.
Analogous carboxamide compounds showing antileukemic activity but lacking the present broad spectrum microbial activity are described in previous publications of the same authority, Shealy et al., Biochem. Pharmacol. 7 674 (1962), and Shealy et al., Nature, 210, 208 (1966).
Comparative experiments showing the lack of activity of analogous prior art carboxamides to typical compounds showing novel broad spectrum microbial activity of the present esters are set out more fully in Examples 26 and 27.
SOLUBILITY The compounds of the present invention, in addition to fair aqueous solubility, are generally soluble in polar and organic solvents such as lower aliphatic alcohols, such as methanol and ethanol; halogenated compounds of the methane series such as chloroform; alkyl esters of aliphatic acids such as ethyl acetate. The ester acid addition salts such as hydrochloride, hydrobromide, hydroiodide find greater hydrophilic solubility due to aqueous affinity of the acid and this is particularly true of the mineral acid addition salt group.
Suitable salts are, for example, the ester acid addition salts from mineral acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid and orthophosphoric acid, or organic acids such as acetic acid, propionic acid, pivalic acid, succinic acid, maleic acid, fumaric acid, lactic acid, malic acid, tartaric acid, citric acid, gluconic acid, L-ascrobic acid, benzoic acid, salicylic acid, methyl sulfonic acid, ethyl disulfonic acid, p-toluenesulfonic acid, naphthalene disulfonic acid and ,B-hydroxyethyl sulfonic acid.
UTILITY The instant compounds have present utility as sanitizing compounds. Thus, a hospital blanket or a toy from the OT. department of the hospital when soiled and contaminated by a mixture of pathogenic organisms including both bacteria and fungi, may be sanitized immediately by soaking or spraying the article with solutions of 50 to 250 ppm. of the active compound. Aqueous solutions of the water-soluble acid addition salts of the esters, alcoholic sprays of the more hydrophobic compounds and foamite applications to other articles about the hospital, such as soiled rugs, illustrate the present utility of the compounds of this invention.
The prospective utility of the compounds of the present invention is as true, extra broad spectrum antibiotics which uniquely are effective against both fungi and bacteria. A pressing problem in modern medicine is to develop chemotherapeutic agents to check secondary infections which develop in long term leukemia patients. For example, J. G. Gruhn, speaking in Cancer (Cancer, vol. 16, 61, 1963) states that secondary micoses are becoming increasingly important as a contributory cause of death in leukemia. Aspergillus and Candida are the most popular micotic organisms-and then cites as causation (l) the diminution of normal flora by antibiotics, and (2) depression of tissues resistance by steroids.
The following articles additionally elaborate and repeat this thesis, Carbone et al., Ann. Internal Med., vol. 60, page 556 (1964); Sidransky et al., Diseases Chest, vol. 19, page 630 (1961); Dorack, R. M., Am. J. Med, vol. 22, page 872 (1957).
The search for a broad spectrum antibiotic which would be truly broad spectrum in that it would cover antifungal or have fungicidal activity effect is not yet complete.
Of the more popular antibacterial drugs now in use, penicillin G is limited to acute bacteriostat action against gram positive bacteria. Streptomycins widely used during the 1950s and active against both gram positive and gram negative bacteria, have recently fallen in disfavor due to sensitivity of the auditory nerve to these drugs. Probably the closest approach of modern therapy to the broad spectrum antibiotics are the tetracyclines. These drugs, still in the phase of development and modification, are active against a wide range of gram positive and gram negative bacteria as well as the rickettsia which causes Rocky Mountain spotted fever, typhus, etc.
Finally, chloramphenicol is a bacteriostat with a range roughly paralleling the tetracyclines and a greater potency against many organisms. However, the drug can cause serious and sometimes fatal blood dyscrasias and its use is limited. Thus, approaching the problem of modern availability of antibacterial drugs, none has a utility as an antifungal agent.
Similarly, approaching the problem from the modern favored antifungal agents, the most popular amphotericin B is without elfect on bacteria, rickettsia and viruses (Goodman and Gilman, The Pharmacological Basis of Therapeutics, third ed. (1965), page 1294).
Further nystatin, a popular polyene fungistat is also stated to be without results or without effect on bacteria, protozoa or viruses. Finally, the equally popular antifungal griseofulvin is devoid of any bacterial activity.
Therefore, there is no marketed drug in modern medicine today which combines broad spectrum antibacterial activity including both gram negative and gram positive action and effective antifungal activity suitable to fill the urgent need for a systemic agent to control secondary infections of leukemia and other cancer patients.
The compounds of the present invention have prospec tive utility to fill this clinical need in that they combine broad antibacterial activity with antifungal activity.
ACTIVITY The triazeno imidazole carboxylic acid esters and the S-diazoimidazole-4-carboxylic acid esters of this invention have inhibitory activity in several different types of microorganisms. Methyl (or 4)-(3,3-dimethyl 1 triazeno)-imidazole-4(or 5)-carb0xylate, the compound of Example 1, for example, inhibits the growth of a wide variety of yeast, filamentous fungi, gram positive and gram negative bacteria, mycobacteria and algae. The antimicrobial activity of these compounds is exemplified by inhibition by methyl 5(or 4)-(3,3 dimethyl-l-triazeno)imidazole-4(or 5)-carboxylate (Example 1), ethyl 5(or 4)-(3- cyclohexyl-3-methyl-l-triazeno)imidazole 4(or 5)-carboxylate (Example 9), or methyl 5-diazoimidazole-4-carboxylate (Example 4) of Streptococcus faecalis, Staphylococcus aureus Bactillus substil is, Sarcina lutes, Escherichia 4 monas aeruginos'a, Mycobacterium smegmatz's, Candida albicans, Hansenula wingal, Saccharomyces cerevisiae, Fusarium oxysporum, Penicillium roquefortz', Chlorelia pyrenoidosa, and strains of these micro-organisms resistant to the action of certain known chemotherapeutic agents.
The relative scarcity of useful antifungal agents in comparison with the many antibacterial agents of microbial and synthetic origins emphasizes the importance of new compounds and structures that display potent antifungal activity and compounds which exert both antibacterial and antifungal activity.
As aforementioned, the need for more and better antifungal drugs has become more urgent because of the increasing incidence and severity of fungal infections associated with debilitating diseases such as cancer, and with the administration of antibiotics, corticosteroids and anticancer drugs. Also, the control of strains of pathogenic bacteria that become resistant to known antibacterial drugs and antibacterial agents requires new chemical structures to which such bacteria are not cross-resistant. For these reasons, novel structures, such as the triazeno imidazole carboxylic acid esters or the 5-diazoimidazole-4-carboxylic acid esters of this invention that possess in many cases both antifungal and antibacterial activity are of obvious interest. Moreover, the few medicinal antifungal agents today are essentially devoid of antibacterial activity and conversely the antibacterial drugs are ineffective against pathogenic fungi. Enhanced importance and novelty therefore derive from inhibitory activity against both the fungi and the bacteria, including mycobacteria, by a single type of structure such as the present compounds, for example, the methyl 5( or 4)-(3,3-dimethyl-l-triazeno) imidaZole-4(or 5)-carboxylate. As prospective utility the economic importance of plant type of germs, both fungal and bacterial, make apparent the importance of novel antifungal and antibacterial compounds to agriculture and horticulture.
PROCESS The triazeno esters may be prepared conveniently from the ester of the corresponding amino compound of the 4(or 5)-carboxylic acid and treating this amino compound with a diazotising reagent and an acid. The starting materials are well known in the art, for example, the methyl 4(or 5)-amino imidazole-5(or 4)-carboxylate used in Examples 1, 2, 3, 4 or 7 and 19 is cited in the Jour. Gen. Chem., USSR, 29, 2366-2368 (1959), a translation of Russian Zhur. Obshchei Khim., 28, 2401 (1959). This Russian article has not only prepared the methyl and ethyl esters, but the alkyl series including the mineral acid addition salts. An additional citation to the same amino starting materials is the Jour. Chem. Soc., 1942, pg. 232, Allsebrook et al. Additionally, where the corresponding nitro derivative is used as the precursor for the aminb as in Example 14, its formula and preparation are described in Berichte, 56, pp. 683-686 (1922). The triazenoimidazole esters are readily prepared by treating an ester (with the desired R substituent) of 5 (or 4)-aminoimidazole4(or 5)-carboxylic acid with a diazotising agent and an acid, in order to form an ester of S-diazornidazole- 4-carboxylic acid which is the intermediate diazo compound. Subsequently, the requisite amine (with the desired R and R substituents) is introduced in sufiicient quantity to neutralize the acid and to react with the diazo group in the cold. Thus, diazotisation of methyl 5(or 4)-amino imidazole-4(or 5)-carboxylate with sodium nitrite and hydrochloric acid followed by addition of 25% aqueous dimethyl amine and extraction of the reaction mixture with chloroform reveals methyl 5 (or 4)-(3,3-dimethyl-ltriazeno) imidazole4( or 5 -carboxylate.
Alternatively, the process may be interrupted to recover the active but sporadically unstable diazo compounds in the form of the intermediate 5-diazoimidazole-4-carboxylic acid ester which may be conveniently extracted from the aqueous diazotisation mixture with organic solvents such as chloroform, or depending on water solubility may be recovered as a precipitate from the solution and collected by filtration. Such a procedure is taught more fully as in Examples 4 through 6 inclusive. Additionally, the diazo derivative may then be treated with an appropriate amine in a two-step or interrupted process to produce the final preferred triazeno compounds.
In general, the production of the diazo compound or diazonium salt which is a nitrous acid derivative of the heterocyclic amine follows conventional procedure in the type reaction for the production of diazo compounds, as for example, set out in Karrer Organic Chemistry, 4th 'Ed., 1950, page 472. The amine and the nitrite salt are reacted in approximately equimolar quantities in the presence of a general excess of at least 2.5 mols of mineral acid, as for example, hydrochloric acid used in many of the examples. The reaction is carried out by immersing in an ice salt bath to reduce the temperature to a range of about -5. The excess of the mineral acid serves to drive the reaction toward the right and the cold treatment is used because many diazo and diazonium compounds are unstable at high temperatures. Thus the diazo compound may be separately recovered.
The production of the triazeno compound is readily made after destruction of excess nitrite with an agent such as sulfamic acid and when the required primary or secondary amine is added the reaction goes at a slightly alkaline pH of 9-10. The compound may be extracted with chloroform, recrystallized from methanol, dried and recovered as the triazeno compound.
EXAMPLE 1 Methy (or 4)-(3,3-dimethyl-1-triazeno)imidazole- 4(or 5)-carboxylate A solution of 5.4 g .of mehyl 5 (or 4)-aminoimidazole- 4(or 5)-carboxylate in 216 m1. of a one-normal (1 N) solution of hydrochloric acid was treated with activated carbon to remove colored impurities. To the colorless filtrate, immersed in an ice-salt bath, was added dropwise during 0.5 hr. a solution of 2.95 g. of sodium nitrite in 25 ml. of water. The yellow solution was stirred in the ice-salt bath for an additional hour, excess nitrite was destroyed by the addition of sulfamic acid, and 55 ml. of 25% aqueous dimethylamine was added. This solution (pH 9-10) was stirred for 1 hour in the ice bath and then extracted six times with 250 ml. portions of chloroform. The extracts were combined, the total extract was dried with magnesium sulfate and treated with activated carbon; and the filtrate from the carbon was freed of solvent under reduced pressure. The pink product was dried in vacuo over phosphorus pentoxide at room temperature, wt. 4.9 g. The yields of crude product ranged from 66- 83%. A solution of the crude product in methanol was stirred with activated carbon, filtered, and reduced to dryness in vacuo. The residue was treated with activated carbon in methanol a second time, and the resulting white solid was dried in vacuo over phosphorus pentoxide at room temperature, weight, 4.3 g.; M.P. 163-165 with decomposition; one spot on a thin-layer chromatogram (silica gel H, 9:1 chloroform-methanol). The methyl 5(or 4)-(3,3-dimethyl-l-triazeno)imidazole-4(0r 5) carboxylate obtained in this manner displayed ultraviolet absorption maxima in methanol at 233 m and 328 m and prominent infrared absorption bands near 1695 cmfl, 1440 cmr 1315 cm.- 1070 cmr Analysis.-Calcd. for C7H11N5O2 (percent): C, 42.64; H, 5.63; N, 35.51. Found (percent): C, 42.90; H, 5.65; N, 35.44.
EXAMPLE 2 Methyl 5 (or 4)-3-n-butyl-3-methyl-l-triazeno)imidazole- 4(or 5)-carboxylate The procedure of Example 1 was employed with the following exceptions: (1) the reaction solution obtained after the addition of the water solution of sodium nitrite to the hydrochloric acid solution of methyl 5 (or 4)- aminoimidazole-4(or 5)- carboxylate was stirred for 0.5 hour, and (2) methyl-n-butylamine was used in lieu of 25% aqueous dimethylamine and was added in sufiicient quantity to raise the pH at least to 9. The product precipitated from the reaction mixture and was collected by filtration, washed well with water, and dried thoroughly at room temperature. From 7.5 g. of methyl 5( or 4)-aminoimidazole-4(or 5 )-carboxylate was obtained 9.1 g. (72% yield) of white crystals of methyl 5 (or 4)-(3-n-butyl-3- methyl-l-triazeno)imidazole-4(or 5) carboxylate, M.P. 167-168 with decomposition.
Analysis.Calcd. for c d-1 N 0 (percent): C, 50.19; H, 7.16; N, 29.27. Found (percent): C, 50.25; H, 7.23; N, 29.21.
EXAMPLE 3 Methyl 5(or 4)-(3-cyclohexyl-3-mehyl-l-triazeno) imida'zole-4- (or 5 -carb0xy1ate The procedure of Example 2 was followed with the exception that methylcyclohexylamine was used in lieu of methyl-n-butylamine. From 5.5 g. of methyl 5(or 4)- aminoimidazole-4(or 5)-carboxylate was obtained 7.2 g. of methyl 5(or 4)-(3-cyclohexyl-3-methyll-triazeno) imidazole-4(or 5 )-carboxylate as white crystals; M.P. 182- l84 with decomposition.
Analysis.-Calcd. for C H N O (percent): C, 54.32; H, 7.22; N, 26.40. Found (percent): C, 54.50; H, 7.38; N, 26.25.
EXAMPLE 4 Methyl 5-diazoimidazole-4-carboxylate A solution of 10 g. of methyl 5(or 4)-aminoimidazole- 4(or 5 )-carboxylate in 200 ml. of 1 N hydrochloric acid was treated with activated carbon to remove colored impurities. To the filtrate immersed in an ice-salt bath was added dropwise during 5 min. a solution of 5.46 g. of sodium nitrite in 20 m1. of water. The reaction mixture was stirred for 1.5 hr. and then extracted 10 times with 200-ml. portions of chloroform. The extracts were combined, the total extract was washed with saturated sodium chloride solution, filtered, and dried with magnesium sulfate. The filtrate from the drying agent was evaporated under reduced pressure at temperatures below 30, and the yellow crystalline methyl 5-diazonimidazole-4-carboxylate so obtained was dried further in a vacuum at room temperature; weight, 8.13 g. (75% yield); M.P. 96. The ultraviolet absorption spectrum of methyl 5- diazoimidazole-4-carboxylate in phosphate buffer at pH 7 displayed a maximum at 314 m and a shoulder at 270 me; its infrared spectrum included prominent bands near 2180 cm.* due to the diazo group and near 1700 cm. due to the ester group.
Analysis.Calcd. for C H N O (percent): C, 39.48; H, 2.65; N, 36.84. Found (percent): C, 39.81; H, 2.98; N, 36.51.
EXAMPLE 5 Ethyl S-diazoimidazole-4-carboxylate To a solution of 1.36 g. of ethyl 5 (or 4)-aminoimidazole-4(or 5 )-carboxylate hydrochloride in 20 ml. of 1 N hydrochloric acid at 0 was added a solution of 546 mg. of sodium nitrite in 5 ml. of water. The pale yellow solution was stirred at 0 for 1 hour and then extracted with four 25-ml. portions of chloroform. The chloroform extracts Were combined, washed with a saturated solution of sodium chloride, dried with magnesium sulfate, filtered, and concentrated under reduced pressure at room temperature. The residual light yellow oil (1.1 g.) crystallized to a yellow crystalline solid; M.P. 45-46 dec. A strong band near 2200 cmrl, characteristic of the diazo group, was present in the infrared spectrum.
Analysis.Calcd. for C H N O (percent): C, 43.38; H, 3.64; N, 33.72. Found (percent): C, 43.40; H, 3.58; N, 33.94.
7 EXAMPLE 6 Octyl--diazoirnidazole-4-carboxylate Octyl 5 (or 4)-aminoimidazole-4(or 5 )-carboxylate hydrochloride was diazotized in hydrochloric acid by a procedure similar to those of Examples 4 and 5. The product precipitated and was separated by filtration, washed thoroughly with Water, and dried under reduced pressure; yields were 75-85%; M.P. 4445'. The product may be purified further by dissolving it in acetone, treating the acetone solution with activated carbon, and evaporating the acetone from the filtrate under reduced pressure. The residual oil crystallizes to a yellow crystalline solid; M.P. 45-46". The infrared absorption spectrum included strong absorption bands near 2190 cmr and 1730 emf, characteristic of a diazo group and an ester group, respectively.
Analysis.Calcd. for C H N O (percent): C, 57.58; H, 7.25; N, 22.38. Found (percent): C, 57.82; H, 7.31; N, 22.59.
EXAMPLE 7 Methyl 5 (or 4) 3- 2-hydroxyethyl -3 -methyl-1- triazeno] imidazole-4 (or 5 -carboxylate Part A.The procedure of Example 1 was followed with the exception that N-rnethylethanolamine was used in lieu of 25% aqueous dimethylamine. The chloroform extract afiorded a clear viscous oil, which was crystallized from a mixture of methanol, ethyl acetate, and hexane. The yield of white crystalline product was 10.5%; M.P. 156l58 with decomposition. An additional quantity was isolated by neutralizing the water layer remaining from the chloroform extraction with hydrochloric acid, reextracting the neutral water layer with chloroform, and crystallizing the oil obtained from the second chloroform extract from a mixture of methanol, ethyl acetate, and hexane. The second portion, M.P. 156-157" dec., amounted to a yield of 14.5% and raised the total yield to 25%.
Part B.-A solution consisting of 12.5 ml. of N-methylethanolamine in 125 ml. of ethyl acetate was prepared and was shielded from light. To this solution 3.14 g. of methyl 5-diazoimidazole-4-carboxylate was added in portions. This addition was made over a period of 1-1.5 hr., and the reaction mixture was stirred for an additional 2.5 hr. in the dark. The precipitated product was collected by filtration, washed thoroughly with ethyl acetate, and dried under reduced pressure; weight, 4.4 g. (98% yield); M.P. 156-157 dec.
Analysis.--Calcd. for C H N O (percent): C, 42.29;
H, 5.77; N, 30.82. Found (percent): C, 42.17; H, 5.87; N, 30.64.
EXAMPLE 8 Ethyl 5 (or 4)-(3-N-butyl-3-methyl-l-triazeno)imidazole- I,
4(or 5) -carboxylate Part A.A solution consisting of 4.75 g. of ethyl 5- dia-zoimidazole-4-carboxylate in 75 ml. of anhydrous ethyl acetate was prepared and was shielded from light. To this solution was added 20 ml. of methyl-n-butylamine, and the mixture was cooled to prevent an excessive rise in the temperature. The mixture, in which a white precipitate soon began to form, was stirred overnight at room temperature in the dark. The white crystalline product was collected by filtration, washed with ethyl acetate, and dried under reduced pressure; weight, 3.7 g.; M.P. 130- 131. Additional ethyl 5(or 4)-(3-n-butyl-3-methyl-1- triazeno)imidazole-4(or 5 )-carboxylate was obtained by diluting the ethyl acetate filtrate with hexane and chilling. White needles were removed by filtration, washed with ethyl acetate, and dried under reduced pressure; weight, 2.36 g.; M.P. 130-131.
Analysis.Calcd. for C I-1 N 0 (percent): C, 52.16; H, 7.56; N, 27.65. Found (percent): C, 52.28; H, 7.64; N, 27.50.
Part B.To a solution of 5.0 g. of ethyl 5(or 4)- aminoimidazole-4(or 5)-carboxylate hydrochloride in 74 m1. of 1 N hydrochloric acid at 0 C. was added during a period of 15 min. a solution of 2.0 g. of sodium nitrite in 20 ml. of water. The resulting solution was stirred in an ice bath for 30 min., the excess nitrite was destroyed with sulfamic acid, and 30 ml. of methyl-n-butylamine Was then introduced. The mixture was stirred for 1.5 hr. and then filtered to remove the first portion of product, which was washed thoroughly with water and dried under reduced pressure; weight, 3.43 g.; M.P. 131. The filtrate was extracted twice with 50-ml. portions of chloroform and the extracts were combined. The total chloroform extract was washed with a saturated aqueous sodium chloride solution, treated with activated carbon, and dried with magnesium sulfate. Evaporation of the chloroform under reduced pressure left an oil that crystallized when it was triturated with a 4:1 mixture of hexane and ethyl acetate. Recrystallization of this solid from a mixture (1: 1) of ethyl acetate and hexane yielded a second portion of crystalline ethyl 5 (or 4)-'(3-n-butyl- 3-methyl-1-triazeno)imidazole 4(or 5) carboxylate; weight, 2.28 g.; M.P. 130131. The infrared spectra of both this material and of the first portion showed them to be identical with specimens of this compound prepared by the procedure of Part A.
EXAMPLE 9 Ethyl 5(or 4)-(3-cyclohexyl-3-methyl-l-triazeno) imidazole-4 (or 5 -carboxylate Part A.--The procedure of Part A of Example 8 was applied to a reaction of ethyl 5-diazoirnidazole-4-carboxylate (4.5 g.) and methylcyclohexylarnine (20 ml.), instead of methyl-n-butylamine, in ethyl acetate (125 ml.), The reaction mixture was stirred for a period of 2 hr. at room temperature instead of the overnight-stirring of Example 8, Part A. The white crystalline product obtained by filtering the reaction mixture represented a yield of 58% (4.31 g.); M.P. dec. The infrared spectrum of this material was identical with that of the analytical sample of Part B. A second crop of the same product amounting to a yield of 16.5% (1.25 g.) was obtained by diluting the filtrate from the first crop with hexane and chilling.
Part B.-The procedure of Part B of Example 8 was employed with the exception that methylcyclohexylarnine was used in lieu of methyl-n-butylamine. The reaction mixture was filtered to remove a precipitate that represented a yield of 80% of ethyl 5(or 4)-(3-cyclohexyl- S-methyl-l-triazeno)imidazole-4(or 5)-carboxylate; M.P. l'68l70 with decomposition.
Analysis.Calcd. for C H N O (percent): C, 55.89; H, 7.58; N, 25.07. Found (percent): C, 55.78; H, 7.58; N, 24.96.
EXAMPLE 10 Ethyl 5(or 4)-(3,3-dimethyl-1-triazeno) imidazole-4( or 5)-carboxylate Part A.-Dimethylamine gas was passed into 75 ml. of ethyl acetate until 13.9 g. had been absorbed. To this solution, cooled with an ice bath, was added, within a 3-minute interval, a solution of 4.7 g. of ethyl 3-diazoimidazole-4 carboxylate in 25 ml. of ethyl acetate. A white solid began to precipitate almost immediately. The mixture was stirred at ice-bath temperature for 2 hr., and the white crystalline ethyl 5 (or 4)-(3,3-dimethyl-l-triazeno)imidaZole-4(or 5)'carboxylate Was separated by filtration, washed with ethyl acetate, and dried under reduced pressure, weight, 3.92 g., M.P. 174-175 dec.
Analysis.Calcd. (percent): C, 45.50; N, 6.21. Found (percent): C, 45.54; H, 6.37.
A second crop of slightly less pure product, which amounted to 400 mg., was precipitated from the filtrate by the addition of ether.
Part B.The procedure of Part B of Example 8 was employed with the exception that 25% aqueous dimethylamine (110 ml.) was used in lieu of methyl-n-butylamine. After 1 hr. of stirring, the reaction mixture was extracted four times with chloroform. The extracts were combined; the total extract was washed with saturated aqueous sodium chloride solution and dried with magnesiurn sulfate; and the chloroform was evaporated under reduced pressure. From 10 g. of ethyl (or 4)-aminoimidazole-4(or 5 -carboxylate hydrochloride was obtained 9.54 g. of the dimethyltriazene derivative; M.P. 174- 175 dec.
Analysis.-Calcd. for C H N O (percent): C, 45.50; H, 6.21; N, 33.16. Found (percent): C, 45.82; N, 6.24; N, 33.30.
EXAMPLE 11 Octyl 5 (or 4) -(3-n-butyl-3-rnethyl-l-triazeno imidazole-4 (or 5 -carboxylate A solution of 24.0 ml. of methyl-n-butylamine in 200 ml. of ethyl acetate was prepared and was shielded from light. To this solution was added, during 1 hr., 4.0 g. of octyl 5-diazoimidazole-4-carboxylate, and the resulting reaction solution was stirred at room temperature overnight. The mixture was then concentrated under reduced pressure to a thick syrup, which was dissolved in ben- Zene and applied to a column of Florisil. The column was eluted successively with hexane, a mixture of hexane (60%) and acetone (40%). Evaporating the solvents under reduced pressure from the hexane-acetone eflluent, triturating the residual oil with hexane, and chilling the mixture resulted in the formation of light pink crystals that were separated by filtration, washed with hexane, and dried under reduced presusre, weight, 2.1 g.; M.P. 6465 dec. The acetone effluent from the Florisil column was treated in the same manner as the hexane-acetone efliuent and yielded an additional 967 mg. of faintly pink crystals of octyl 5(or 4)-(3-n-butyl-3-methyl-l-triazeno)imidazole 4(or 5) carboxylate. The ultraviolet spectra of this compound in phosphate buffer solution at pH 7 showed absorption maxima of 237 m and at 330 III/L and in 0.1 M aqueous sodium hydroxide solution, at 249 mp. and 340 m,u.
Analysis.--Calcd. for C H N O (percent): C, 60.50; H, 9.26; N, 20.75. Found (percent): C, 60.55; H, 2.24; N, 20.53.
EXAMPLE 12 Octyl 5 (or 4) (3-cyclohexyl-3-methyl-triazeno) imidazole-4- (or 5 -carboxylate The procedure of Example 11 was employed with the following exceptions: (1) rnethylcyclohexylamine was used in lieu of methyl-n-butylamine and (2) the Florisil column was eluted successively with hexane, a solvent mixture composed of 50% hexane and 50% acetone, and a solvent mixture composed of 40% hexane and 60% acetone. Crystalline octyl 5(or 4)-(3-cyclohexyl-3-methyl-1-triazeno)imidazole-4 (or 5 -carboxylate isolated from the two hexane-acetone efiiuents by the procedure of Example 11 amounted to 3.3 g., M.P. 94-95. Ultraviolet absorption maxima at 222 my and 326 mg and at 249 my. and 340 m were present in the spectra of this compound dissolved in 0.1 N hydrochloric acid and in 0.1 N aqueous sodium hydroxide, respectively.
Analysis.-Calcd. for C H N O (percent): C, 62.78; N, 9.15; N, 19.27. Found (percent): C, 62.71; H, 9.10; N, 19.29.
EXAMPLE 13 Octyl 5 (or 4)-(3,3-dimethyl-l-triazeno) imidazole-4(or 5)-carboxylate Dimethylamine gas was passed into 250 ml. of ethyl acetate until 65 g. had been absorbed. To this solution cooled in an ice bath, was added 7.0 g. of octyl S-diazoimidazole-4-carboxylate during a period of one hour. The
resulting solution was stirred at room temperature overnight and then treated with activated carbon. Evaporation of the ethyl acetate under reduced pressure left the crude solid product which was purified by chromatography on Florisil by a procedure similar to those of Examples 11 and 12. The acetone efiluent yielded 5.8 g. of crystalline solid; M.P. 104-105 Alternatively, the crude product may be purified by treating an ethanol solution or an ethyl acetate solution of the crude material with activated carbon and then diluting the filtrates with water or with hexane, respectively. White crystals of octyl 5(or 4) (3,3-dimethyl-l-triazeno)imidazole-4(or 5)-carboxylate so obtained melt at 104-105" and display ultraviolet absorption maxima at 236 mp. and 329 m in phosphate buffer solution and at 249 my and 339 me in 0.1 N aqueous sodium hydroxide solution.
Analysis.-Calcd. for C H N O (percent): C, 56.94; H, 8.53; N, 23.69. Found (percent): C, 56.90; H, 8.35; N, 23.74.
EXAMPLE 14 Octyl 5 (or 4)-aminoimidazole-4(or 5 )-carboxylate hydrochloride To a mixture of 3.5 g. of a 5% palladium-on-charcoal catalyst and 50 ml. of methanol was added 5.9 g. of octyl 5 (or 4)-nitroimidazole-4(or 5)-carboxylate and an additional 50 ml. portion of methanol. Hydrogen was introduced, after flushing air from the reaction vessel, first with nitrogen and then with hydrogen, at approximately atmospheric pressure, and the mixture was stirred until the amount of hydrogen absorbed approximated the theoretical amount. The catalyst was removed by filtration under a current of nitrogen, the filtrate was saturated with dry hydrogen chloride, and the mixture was concentrated under reduced pressure until a white solid (6.1 g.) remained. The White solid was dissolved in a mixture of ml. of ether and 15 ml. of ethanol, the turbid mixture was filtered, and the colorless filtrate was diluted, while hot, with 100 ml. of hexane. White crystals of octyl 5 (or 4)-aminoimidazole-4(or 5)-carboxylate hydrochloride that precipitated from the cooled solution were separated by filtration, washed with a 1:1 mixture of ether and hexane, and dried under reduced pressure, weight, 4.02 g.; M.P. The ultraviolet spectrum of a 0.1 M hydrochloric acid solution showed maxima at 239 my and 266 my.
Analysis.--Calcd. for C12H21N302HC]. (percent): C, 52.26; H, 8.04; N, 15.24. Found (percent): C, 52.08; H, 8.04; N, 15.14.
EXAMPLE 15 Octyl 5 (or 4) -nitroimidazole-4 (or 5 -carboxylate A mixture of 4.0 g. of 5(or 4)-nitroimidazole-4(or 5)- carboxylic acid and 50 ml. of octyl alcohol was saturated with dry hydrogen chloride at 10. The reaction mixture was heated at 8085 for 1 hr., cooled and resaturated with hydrogen chloride, and heated again at 90 for 1 hr. Thirty milliliters of benzene was added and the mixture was heated at the reflux temperature with a Dean-Stark trap placed between the condenser and the reaction flask to remove water. When the removal of water was complete, the reaction mixture was concentrated under reduced pressure until a white solid remained. Recrystallization of this residue from a mixture of ethanol and water yielded 5.925 g. of white platelets; M.P., -171".
Analysis.Calcd. for C H N O (percent): C, 53.51; H, 7.11; N, 15.60. Found (percent): C, 53.86; H, 7.01; N, 15.68.
EXAMPLE 16 Methyl 5 (or 4)-[3-(p-chlorophenyl)-1-triazeno] imidazole-4 (or 5 -carboxylate A solution consisting of 2.31 g. of para-chloroaniline in 30ml. of anhydrous ethyl acetate was prepared and was shielded from light. To this stirred solution was added, in portions, 951 mg. of methyl 5-diazoimidazole-4-carboxylate during a period of 15 min. The reaction mixture was stirred for an additional 20 hrs. in the dark. The precipitated product was collected by filtration, washed thoroughly with ethyl acetate, and dried under reduced pressure at 56, weight, 657 mg. (65% yield). This compound decomposes explosively at approximately ISO-185 and will decompose more slowly at lower temperatures.
Analysis.-Calcd. for C H ClN O (percent): C, 47.25; H, 3.61; N, 25.04. Found (percent): C, 47.47; H, 3.77; N, 25.02.
EXAMPLE 17 Methyl 5 (or 4) 3- (3,4-dichlorophenyl) -l-triazeno] 4 (or 5 -carb oxylate The procedure of Example 16 was employed except that a -fold molar excess of 3,4-dichloraniline was used in lieu of para-chloroaniline. The yield of the first crop of the product was 34%.
Analysis.Calcd. for C 'I-I Cl N O (percent): C, 42.05; H, 2.89; N, 22.30. Found (percent): C, 41.80; H, 3.22; N, 22.05.
Continued stirring of the filtrate from the first crop of product resulted in the precipitation of additional product that increased the yield to 52%.
EXAMPLE 18 Methyl 5 (or 4)-(3-methyl-1-triazeno)imidazole- 4 (or 5 -carboxylate To a solution (shielded from light) of anhydrous methylamine in 20 ml. of anhydrous ethyl acetate at -5 was added, during a 5-minute period, 500 mg. of methyl 5-diazoimidazole-4-carboxylate. The reaction mixture was stirred for an additional 5 min., and the precipitated product was collected by filtration, washed with ethyl acetate, and dried under reduced pressure at room temperature, weight, 520 mg. (87% yield). The compound decomposes explosively at approximately 125130. The analytical sample was dried under reduced pressure at room temperature for 40 hrs. and at 56 for 1 hr.
Analysis.Calcd. for C H N O (percent): C, 39.34;
i H, 4.96; N, 38.24. Found (percent): C, 39.20; H, 5.10;
EXAMPLE l9 Methyl 5(or 4)-(3,3-dibutyl-1-triazeno)imidazole- 4(or 5)-carboxylate The procedure of Example 1 was applied to 1.41 g. of methyl 5 (or 4)-aminoimidazole-4(or 5)-carboxylate with the following exceptions: a large excess of dibutylamine was used in lieu of 25% aqueous dimethylamine, the two-phase reaction mixture was allowed to stir at 20 overnight, and the isolation procedure differed in details as described below. The reaction mixture was extracted three times with ethyl acetate, the extracts were combined, and the total extract was washed with water and dried with magnesium sulfate. Evaporation of the solvent left a syrup that was converted to a solid by trituration with a 95:5 mixture of cyclohexane and chloroform. The solid was collected by filtration, washed wtih cyclohexane, and dried under reduced pressure at room temperature: weight, 1.14 g.; M.P. 121. Concentration of the filtrate yielded a solid that was triturated with cyclohexane and separated and dried as before; weight, 1.1 g. (total yield, 80%); M.P. 121. The two portions were treated in hot ethyl acetate with activated carbon. Dilution of the filtrate with hot cyclohexane afforded 1.75 g. of white needles; M.P. 122-123 dec.
Analysis.Calcd. for C H N O (percent): C, 55.50; H, 8.24; N, 24.95. Found (percent): C, 55.38; H, 8.12; N, 25.16.
EXAMPLE Ethyl 5 (or 4) -[3-(2-hydroxyethyl) -3-methyl-1-triazeno]- imidazole-4 (or 5) -carboxylate The procedure of Part A of Example 8 was employed except that N-methylethanolamine was used in lieu of methyl-n-butylamine. The reaction mixture was diluted with cyclohexane, and, after 0.5 hr. of stirring, the product was collected by filtration, washed with cyclohexane, and dried under reduced pressure at 56; yield, M.P., 138-l39 dec. This compound may be further purified by recrystallization from a mixture of ethanol and cyclohexane, M.P. 140 dec.
Analysis.-Calcd. for C H N O (percent): C, 44.80; H, 6.27; N, 29.03. Found (percent): C, 44.56; H, 6.23; N, 29.20.
EXAMPLE 21 Ethyl 5 (or 4) 3-methyl-3 -n-octyl-l-triazeno imidazole- 4(or 5 -carboxylate The method of part B of Example 7 was employed except that methyl-n-octylamine was used in lieu of N- methylethanolamine and ethyl 5-diazoimidazole-4-carboxylate was employed in lieu of methyl S-diazoimidazole- 4-carboxylate. The reaction mixture, after 2 hr. of stirring, was diluted with cyclohexane. White crystals were collected by filtration, washed with a 1:2 mixture of ethyl acetate and cyclohexane, and dried under reduced pressure at 56, the yield from 400 mg. of the diazo compound was 510 mg. (69% M.P. 124-125 dec. A specimen for analysis was recrystallized by dissolving it in ethanol, treating the ethanol solution with activated carbon, and diluting the filtrate with hexane; M.P. dec.
Analysis.-Calcd. for C H N O (percent): C, 58.21; H, 8.81; N, 22.64. Found (percent): C, 58.37; H, 9.00; N, 22.78.
EXAMPLE 22 Ethyl 5 (or 4)-(3,3-dicyclohexyl-l-triazeno)imidazole- 4(or 5)-carboxylate The procedure of Example 21 was employed with the exception that dicyclohexylamine was used in lieu of methyl-n-octylamine. From 400 mg. of the diazo compound there was obtained 550 mg. (65% yield) of the desired product; M.P. 170-175 dec. An ethanol solution of the white solid was treated with activated carbon, the filtrate was diluted with cyclohexane, and the resulting solution was concentrated under reduced pressure to a white solid that was washed with hexane and dried under reduced pressure at 56; M.P. 170-175 dec.
Analysis.Calcd. for C H N O (percent): C, 62.21; H, 8.41; N, 20.17. Found (percent): C, 62.11; H, 8.42; N, 19.95.
EXAMPLE 23 2-diethylaminoethyl 5 (or 4) 3 ,3-dimethyl-1-triazeno imidazole-4 (or 5 -carboxylate The method employed was similar to that of Example 1 with some modifications in the details of the operations. A solution of mg. of sodium nitrite in 5 ml. of water was added at 0 to a solution of 449 mg. of 2-diethylaminoethyl 5(or 4)-aminoimidazole-4(or 5)-carboxylate hydrochloride in 25 ml. of 1 N hydrochloric acid, and the resulting solution was stirred at 0 C. for 45 min. The excess nitrite was destroyed by the addition of sulfamic acid, and 5 ml. of 25% aqueous dimethylamine was added. The mixture was stirred in the absence of light for 1 hr., saturated with sodium chloride, and extracted three times with 35-ml. portions of ethyl acetate. The extracts were combined, the total extract washed with water and dried with magnesium sulfate, and the ethyl acetate was evaporated. The residual oil crystallized: yield, 273 mg. (56.5%); M.P. 114. Extraction of the aqueous layer in similar fashion with two 50-ml. portions of chloroform aiforded an additional 124 mg. (26% yield); M.P. 114". This compound may be recrystallized from a mixture of ethyl acetate and cyclohexane; M.P. 114.
Analysis.--Calcd. for C H N O (percent): C, 51.05; H, 7.85; N, 29.77. Found (percent): C, 51.14; H, 7.98; N, 29.92.
13 EXAMPLE 24 Z-diethylaminoet-hyl (or 4) 3 -cyclohexyl-3 -methyll-triazeno) imidazole-4 (or 5 -carboxylate The method of Example 23 was employed except that methylcycolhexylamine, in excess, was used in lieu of 25% aqueous dimethylamine, the reaction time was 2 hr. instead of 1 hr., and only chloroform (3 portions) was used to extract the product. The syrup obtained from the chloroform was applied to a column of Florisil. The column was eluted successively with hexane and with a 1:1 mixture of hexane and acetone. Evaporation of the solvents from the hexane-acetone effluent left a syrup that crystallized: yield, 52%; M.P. 118. The crude product may be purified by recrystallization from a mixture of ethyl acetate and cyclohexane; M.P. 124.
Analysis.-Calcd. for C17H3N502 (percent): C, 58.25; H, 8.63; N, 23.98. Found (percent): C, 58.46; H, 8.37; N, 23.89.
EXAMPLE 25 Z-diethylaminoethyl 5 (or 4)-aminoimidazole-4 (or 5 carboxylate hydrochloride A mixture of 1.0 g. of 2-diethylaminoethy1 5 (or 4)- nitroimidazole-4 (or 5)-carboxy1ate hydrochloride, 100 ml. of ethanol, and 500 mg. of 5% palladium-on-charcoal catalyst was treated with hydrogen by the procedure of Example 14. After the catalyst had been removed by filtration, the solvent was evaporated under reduced pressure. The residual glass was allowed to stand under ethyl acetate. It crystallized and the crystals of 3-diethylaminoethyl 5 (or 4)-aminoimidazole-4(or 5)-carboxylate hydrochloride were collected by filtration, washed with ethyl acetate, and dried under reduced pressure at 56; yield, 810 mg. (90%); M.P. 142-144". An analytical sample was obtained by recrystallizing a 300 mg. specimen from a mixture of 4 m1. of ethanol, 12 m1. of ethyl acetate, and 15 ml. of hexane; recovery, 77%; M.P. 146- 148.
Analysis.-Calcd. for C H N O -HCl (percent): C, 45.72; H, 6.91; N, 21.32. Found (percent): C, 45.83; H, 6.80; N, 21.62.
COMPARATIVE EXAMPLE 26' Compound I, 5 (or 4) (3,3 dimethyl 1 triazeno) imidazole-4( or 5)-carboxamide, has the same structure as Example 1 except that the ester group of Example 1 has been replaced by an amide group in Compound I.
Using the paper-disc, agar-diffusion assay (Pittillo et al. Antimicrobial Agents and Chemotherapy (1964)), several important differences in antimicrobial activity were noted between Compound I and Example 1, as follows:
(1) At a concentration of 100 micrograms per disc, Compound I did not inhibit the growth of any of the nonfilamentous or filamentous fungi tested except for Penicilliam rubrum. These assays included more than 25 strains of Candida alcibans; 12 other Candida species, including Candida quilliermondii, Candida Kruse-i, and Candida tropicallis, Hansen ula wingei, Klockera brevz's, Saccharomyces cerevisiae, Saccharamyces carisbergensis, Beuveria tenelia, Fusarium oxysporum, Neurospora sitophila, Penicillium roqueforti, Phycomyces nitens, and Rhizopus stolonifer. In contrast, Example 1 inhibited all of these fungi.
(2) Among the dysenteny bacteria, Compound I did not inhibit the growth of three species (S. flexneri, S. dysenteriae, and S. bovlii) of Shigella at 100 micrograms per disc, Example 1 did.
(3) Among the typhoid and paratyphoid bacteria, Compound \I did not inhibit Salmonella typhimuim, S. asiaticas, S. choleraesuis, and S. panama at 100 meg/disc; Example 1 did. Both compounds inhibited S. typhosa.
(4) Compound I did not inhibit Klebsiella pneamoniae, Sarcina lutea, or Lactobacillus casei at 100 meg/disc; Example 1 did.
(5) At a concentration of 10 micrograms per disc, Example 1 inhibited Proteus mirabilis and 7 strains of Proteas vulgaris, several strains of Pseudomonas aeruginosa, and more than 25 strains of Staphylococcus aureus. At the same concentration Compound I did not inhibit these bacteria except for a trace of inhibition of 2 strains of S.
aureus.
(6) At a concentration of l mcg./ disc, Example 1 produced inhibitory zones of 20 millimeters, or greater, in diameter in tests versus four species of the genus Mycobacterium; at the same concentration, Compound I produced only trace inhibition.
It is apparent that Compound I is not inhibitory to fungi, whereas Example 1 inhibits a broad spectrum of fungi. Furthermore, Compound I is inferior to Example 1 in antibacterial activity.
COMPARATIVE EXAMPLE 27 Example -2 Rs mbutyl Compound II: Rszn-butyl Example 3: R zcyclohexyl Compound III: R cychohexy'l In Table I all of the fungi that have been tested for sensitivity to all four compounds (Compound H, Compound III, Example 2, Example 3) are listed together with the zones of inhibition.
TABLE I Zones of inhibition 1 mcg./disc) Compound Exam- Exam- II III pie 2 ple 3 Candida albicams 2 Nt. 0 34 32 Fusarium ozysporium 0 0 30 25 Aspergillus niger 0 0 25 22 Rhizopus slolonifer. 0 0 21 17 Alternuria solonL 0 0 24 17 Scopulariopsis sp. 0 0 33 34 Beaaueria tenella 0 0 30 30 Penlcilllu'm 'notatam O 0 36 32 Neurospora sz'tophila 0 0 26 25 Saccharomyces clorevisiae B 17 Nt. 44 36 1 The numbers in the table beneath a, compound are the diameters in millimeters of the zones of inhibition, surrounding and including the paper disc (diameter=12.7 millimeters), produced by that compound. Nt.=not tested.
2 Mt. Vernon (SR1 -1).
3 ATCC 4098.
Again, the carboxamide compounds II and III showed no fungistatic activity and limited antibacterial activity, whereas the ester compounds of Example 2 and Example 3 showed activity in both microbial areas.
What is claimed is:
N C 00R:
N Nz
where R is C -C alkyl, diethylaminoethyl, or mineral acid addition salts thereof.
15 2. Methyl 5-diazoimidazo1e-4-carboxy1ate. 3. Ethyl 5-diazohnidazole-4-carboxylate. 4. Octyl 5-diazoimidazo1e-4-carboxylate.
References Cited UNITED STATES PATENTS 2/ 1961 Moore et a1 260--141 X OTHER REFERENCES Okamoto et al., Index Chemicus, vol. 24, 73991 (1/ 2/67).
16 Patel et 21., Chemistry and Industry, vol. of 1961, No. 30, p. 1163.
Shealy et aL, J. Org. Chem., vol. 27, pp. 2150 to 2154 (1962).
Shealy et al., J. Org. Chem, v01. 26, pp. 2396 to 2401 (1961).
FLOYD D. HIGEL, Primary Examiner US. Cl. X.R.
US51747*A 1967-09-14 1970-04-28 Diazo derivatives of imidazole carboxylic acid esters Expired - Lifetime US3654257A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66765967A 1967-09-14 1967-09-14
US5174770A 1970-04-28 1970-04-28

Publications (1)

Publication Number Publication Date
US3654257A true US3654257A (en) 1972-04-04

Family

ID=26729790

Family Applications (1)

Application Number Title Priority Date Filing Date
US51747*A Expired - Lifetime US3654257A (en) 1967-09-14 1970-04-28 Diazo derivatives of imidazole carboxylic acid esters

Country Status (1)

Country Link
US (1) US3654257A (en)

Similar Documents

Publication Publication Date Title
US3644363A (en) 1 4-dioxidoquinoxalinyl nitrones
DE3007006C2 (en) Quinolonecarboxylic acid derivatives, their salts, processes for their preparation and agents containing these derivatives
US3489805A (en) 2,3-dihalophenyl-3-iodopropargyl ethers
DE69915487T2 (en) ERYTHROMYCIN DERIVATIVES WITH ANTIBIOTIC EFFECT
CH397657A (en) Process for the preparation of tetracycline compounds
DD203723A5 (en) PROCESS FOR THE PREPARATION OF BIS ESTERS OF 1,1-ALKANDIOLS WITH 6-BETA-HYDROXYMETHYLPENICILLANIC ACID 1,1-DIOXIDE AND BETA-LACTAMANTIBIOTIKA
US4002754A (en) Substituted piperazinyliminorifamycins
Thompson et al. Stendomycin: a new antifungal antibiotic
US3654257A (en) Diazo derivatives of imidazole carboxylic acid esters
US3649613A (en) Triazeno compounds
DE2229223C3 (en) 2-Nitro-S-imidazole derivatives and processes for their preparation
US4044130A (en) Compositions for the control of microorganisms
US3207660A (en) Process for inhibiting growth of microorganisms
US3345370A (en) 4-(n-mono-substituted) hydrazones of 4-dedimethylamino-4-oxo-tetracycline
US4214002A (en) Preservation of aqueous systems with 2-chloro-3-oxobutyramide derivatives
DE2521046A1 (en) 3- (5-NITROIMIDAZOL-2-YL) -PYRAZOLO SQUARE BRACKET ON 3.4 SQUARE BRACKET FOR PYRIMIDINE AND THE METHOD FOR THEIR MANUFACTURE
US3522250A (en) Derivatives of 7-aminocephalosporanic acid
US4035421A (en) N-(3,4,-dichlorophenyl)-2-phenylethenesulfonamide
US4016158A (en) Cephalosporin derivatives
US3485838A (en) Pyridazine derivatives
US3962317A (en) D-3,6-Diaminohexanoic acid 2-(carboxymethyl)-2-methylhydrazide, process of preparing and intermediates of said process
US4097668A (en) 2- (P-Methoxy-benzoyl)-hydrazono-formyl!-quinoxaline-1,4-dioxide
US3819642A (en) 2-(5-nitro-2-thiazolyl)-benzimidazoles
US3264185A (en) Antibiotic pa 166 and method of preparing
DE1906586C3 (en) 9 Alpha-fluoro-16-fluoromethylene-prednisolone-21-oenanthate, process for its production and pharmaceutical preparation containing it